MicroRNA-185 inhibits cell proliferation and induces cell apoptosis by targeting VEGFA directly in von Hippel-Lindau-inactivated clear cell renal cell carcinoma

Urologic Oncology: Seminars and Original Investigations

Volumn 33, Issue 4, 2015, Pages 169.e1-169.e11

  Ma, Xin ^a   Shen, Donglai ^a   Li, Hongzhao ^a   Zhang, Yu ^a   Lv, Xiangjun ^a   Huang, Qingbo ^a   Gao, Yu ^a   Li, Xintao ^a   Gu, Liangyou ^a   Xiu, Shaoxi ^a   Bao, Xu ^a,b   Duan, Junyao ^a,b   Zhang, Xu ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b NANKAI UNIVERSITY   (China)

Author keywords

Apoptosis; Clear cell renal cell carcinoma; MicroRNA 185; Proliferation; VEGFA; VHL

Indexed keywords

CASPASE 3; CASPASE 9; CYCLIN D1; MESSENGER RNA; MICRORNA; MICRORNA 185; SMALL INTERFERING RNA; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN A; VON HIPPEL LINDAU PROTEIN; MIRN185 MICRORNA, HUMAN; VEGFA PROTEIN, HUMAN; VHL PROTEIN, HUMAN;

ADULT; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BINDING SITE; BODY MASS; CANCER INHIBITION; CANCER SIZE; CANCER STAGING; CELL CYCLE PROGRESSION; CELL FUNCTION; CELL PROLIFERATION; CLINICAL ARTICLE; COLONY FORMATION; CONTROLLED STUDY; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY CARCINOMA; KIDNEY PARENCHYMA; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENAL CANCER CELL LINE; AGED; BIOSYNTHESIS; DOWN REGULATION; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENE SILENCING; GENETIC TRANSFECTION; GENETICS; KIDNEY TUMOR; MIDDLE AGED; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

AGED; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, RENAL CELL; CELL PROLIFERATION; DOWN-REGULATION; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; KIDNEY NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; REAL-TIME POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 85006298141     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2015.01.003     Document Type: Article

References (37)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., et al. Cancer statistics, 2008. CA Cancer J Clin 2008, 58:71-96.
2. Ljungberg B., Cowan N.C., Hanbury D.C., Hora M., Kuczyk M.A., Merseburger A.S., et al. EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol 2010, 58:398-406.
3. Coyne D.W. Influence of industry on renal guideline development. Clin J Am Soc Nephrol 2006, 2:3-7.
4. Linehan W.M., Bratslavsky G., Pinto P.A., Schmidt L.S., Neckers L., Bottaro D.P., et al. Molecular diagnosis and therapy of kidney cancer. Annu Rev Med 2010, 61:329-343.
5. Gossage L., Eisen T. Alterations in VHL as potential biomarkers in renal-cell carcinoma. Nat Rev Clin Oncol 2010, 7:277-288.
6. Albiges L., Salem M., Rini B., Escudier B. Vascular endothelial growth factor-targeted therapies in advanced renal cell carcinoma. Hematol Oncol Clin North Am 2011, 25:813-833.
7. Santarpia L., Nicoloso M., Calin G.A. MicroRNAs: a complex regulatory network drives the acquisition of malignant cell phenotype. Endocr Relat Cancer 2009, 17:F51-F75.
8. Trang P., Weidhaas J.B., Slack F.J. MicroRNAs as potential cancer therapeutics. Oncogene 2008, 27:S52-S57.
9. Hirata H., Hinoda Y., Ueno K., Nakajima K., Ishii N., Dahiya R. MicroRNA-1826 directly targets beta-catenin (CTNNB1) and MEK1 (MAP2K1) in VHL-inactivated renal cancer. Carcinogenesis 2012, 33:501-508.
10. Mikhaylova O., Stratton Y., Hall D., Kellner E., Ehmer B., Drew A.F., et al. VHL-regulated MiR-204 suppresses tumor growth through inhibition of LC3B-mediated autophagy in renal clear cell carcinoma. Cancer Cell 2012, 21:532-546.
11. Biggar K.K., Kornfeld S.F., Storey K.B. Amplification and sequencing of mature microRNAs in uncharacterized animal models using stem-loop reverse transcription-polymerase chain reaction. Anal Biochem 2011, 416:231-233.
12. Liu S., Ma X., Ai Q., Huang Q., Shi T., Zhu M., et al. NOTCH1 functions as an oncogene by regulating the PTEN/PI3K/AKT pathway in clear cell renal cell carcinoma. Urol Oncol 2013, 31:938-948.
13. Motzer R., Hutson T., Tomczak P., Michaelson M., Bukowski R., Rixe O., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007, 356:115-124.
14. Escudier B., Eisen T., Stadler W., Szczylik C., Oudard S., Siebels M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356:125-134.
15. Tsukigi M., Bilim V., Yuuki K., Ugolkov A., Naito S., Nagaoka A., et al. Re-expression of miR-199a suppresses renal cancer cell proliferation and survival by targeting GSK-3 β. Cancer Lett 2012, 315:189-197.
16. Majid S., Saini S., Dar A.A., Hirata H., Shahryari V., Tanaka Y., et al. MicroRNA-205 inhibits SRC-mediated oncogenic pathways in renal cancer. Cancer Res 2011, 71:2611-2621.
17. Saini S., Yamamura S., Majid S., Shahryari V., Hirata H., Tanaka Y., et al. MicroRNA-708 induces apoptosis and suppresses tumorigenicity in renal cancer cells. Cancer Res 2011, 71:6208-6219.
18. Cao Y., E G, Wang E., Pal K., Dutta S.K., Bar-Sagi D., et al. VEGF exerts an angiogenesis-independent function in cancer cells to promote their malignant progression. Cancer Res 2012, 72:3912-3918.
19. Chai Z.T., Kong J., Zhu X.D., Zhang Y.Y., Lu L., Zhou J.M., et al. MicroRNA-26a inhibits angiogenesis by down-regulating VEGFA through the PIK3C2alpha/Akt/HIF-1alpha pathway in hepatocellular carcinoma. PloS One 2013, 8:e77957.
20. Hsu C.Y., Hsieh T.H., Tsai C.F., Tsai H.P., Chen H.S., Chang Y., et al. miRNA-199a-5p regulates VEGFA in endometrial mesenchymal stem cells and contributes to the pathogenesis of endometriosis. J Pathol 2014, 232:330-343.
21. Wang W., Ren F., Wu Q., Jiang D., Li H., Shi H. MicroRNA-497 suppresses angiogenesis by targeting vascular endothelial growth factor A through the PI3K/AKT and MAPK/ERK pathways in ovarian cancer. Oncol Rep 2014, 32:2127-2133.
22. Olsen P.H., Ambros V. The lin-4 regulatory RNA controls developmental timing in Caenorhabditis elegans by blocking LIN-14 protein synthesis after the initiation of translation. Dev Biol 1999, 216:671-680.
23. Giraldez A.J., Mishima Y., Rihel J., Grocock R.J., Van Dongen S., Inoue K., et al. Zebrafish MiR-430 promotes deadenylation and clearance of maternal mRNAs. Science 2006, 312:75-79.
24. Guo H., Ingolia N.T., Weissman J.S., Bartel D.P. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 2010, 466:835-840.
25. Coller J., Parker R. Eukaryotic mRNA decapping. Annu Rev Biochem 2004, 73:861-890.
26. Tang H., Wang Z., Liu X., Liu Q., Xu G., Li G., et al. LRRC4 inhibits glioma cell growth and invasion through a miR-185-dependent pathway. Curr Cancer Drug Targets 2012, 12:1032-1042.
27. Qu F., Cui X., Hong Y., Wang J., Li Y., Chen L., et al. MicroRNA-185 suppresses proliferation, invasion, migration, and tumorigenicity of human prostate cancer cells through targeting androgen receptor. Mol Cell Biochem 2013, 377:121-130.
28. Akcakaya P., Ekelund S., Kolosenko I., Caramuta S., Ozata D.M., Xie H., et al. miR-185 and miR-133b deregulation is associated with overall survival and metastasis in colorectal cancer. Int J Oncol 2011, 39:311-318.
29. Li Q., Wang J.X., He Y.Q., Feng C., Zhang X.J., Sheng J.Q., et al. MicroRNA-185 regulates chemotherapeutic sensitivity in gastric cancer by targeting apoptosis repressor with caspase recruitment domain. Cell Death Dis 2014, 5:e1197.
30. Wang J., He J., Su F., Ding N., Hu W., Yao B., et al. Repression of ATR pathway by miR-185 enhances radiation-induced apoptosis and proliferation inhibition. Cell Death Dis 2013, 4:e699.
31. Takahashi Y., Forrest A.R., Maeno E., Hashimoto T., Daub C.O., Yasuda J. MiR-107 and MiR-185 can induce cell cycle arrest in human non small cell lung cancer cell lines. PLoS One 2009, 4:e6677.
32. Campbell M., Li X., Chen Y.-T., Josson S., Mukhopadhyay N.K., Kim J., et al. MicroRNA-185 and 342 inhibit tumorigenicity and induce apoptosis through blockade of the SREBP metabolic pathway in prostate cancer cells. PLoS One 2013, 8:e70987.
33. Chen B, Zhang C, Dong P, Guo Y, Mu N. Molecular regulation of cervical cancer growth and invasion by VEGFa. Tumour Biol. 2014;35:11587-93.
34. Dias S., Shmelkov S.V., Lam G., Rafii S. VEGF(165) promotes survival of leukemic cells by Hsp90-mediated induction of Bcl-2 expression and apoptosis inhibition. Blood 2002, 99:2532-2540.
35. Lessene G., Czabotar P.E., Colman P.M. BCL-2 family antagonists for cancer therapy. Nat Rev Drug Discov 2008, 7:989-1000.
36. Patard J.J., Rioux-Leclercq N., Masson D., Zerrouki S., Jouan F., Collet N., et al. Absence of VHL gene alteration and high VEGF expression are associated with tumour aggressiveness and poor survival of renal-cell carcinoma. Br J Cancer 2009, 101:1417-1424.
37. Kim W.Y., Kaelin W.G. Role of VHL gene mutation in human cancer. J Clin Oncol 2004, 22:4991-5004.